Picture Kentro Design Corporate and Web Design for Start Ups 650x80px
Document › Details

Calliditas Therapeutics AB. (7/2/20). "Press Release: Exercise of Over-allotment Option and End of the Stabilization Period".

Region Region United States (USA)
Organisations Organisation Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
  Group Calliditas Therapeutics (Group)
  Organisation 2 Nasdaq Global Select Market
  Today Nasdaq Global Market
  Group Nasdaq OMX (Group)
Products Product investment banking
  Product 2 Nefecon®
Index term Index term Calliditas Therapeutics–SEVERAL: investment, 202005–202007 US IPO $81m+$6.9m with w 8.3m+707k common shares as ADSs at Nasdaq Global Market
Persons Person Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
  Person 2 Widell, Mikael (Pharmalink AB 201708– Head of Communications before Cord Communications + Nordic Capital)

Record changed: 2020-10-21


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Calliditas Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

» top